艾昆玮-印度医药市场季度洞察-2024年第一季度 Indian Pharmaceutical Market Quarterly Insights – Q1 2024(Jan-Mar)

IndianPharmaceutical

MarketQuarterlyInsights

-Q12024(Jan-Mar)

ReportReleaseDate:May2024

Dataset:TSAMarch2024

©2024.Allrightsreserved.IQVIA®isaregisteredtrademarkofIQVIAInc.intheUnitedStates,theEuropeanUnion,andvariousothercountries.

Disclaimer

IQVIAisnotan“authorisedperson”forthepurposesoftheFinancialServicesandMarketsAct2000(“FSMA”)anddoesnotprovideinvestmentadviceorcarryonanyotherregulatedactivityunderPartIIoftheFSMA2000(RegulatedActivities)Order2001

Theforecasts,projections,andrelatedinformationcontainedhereinaremadeandprovidedsubjecttotheassumptions,methodologies,caveats,andvariablesdescribedinthisreportandarebasedonthirdpartysourcesanddatareasonablybelievedtobereliable.No

warrantyismadeastothecompletenessoraccuracyofsuchthirdpartysourcesordata

Thisreport,inpartorinwhole,isnotintendedtoconstituteinvestmentadvice,andisnotarecommendationtopurchaseornotpurchase,anendorsementof,oranopinionastothevalueof,anysecurityoranyinvestmentinstrumentofanyentity

Aswithanyattempttoestimatefutureevents,theforecasts,projections,conclusions,andotherinformationincludedhereinaresubjecttocertainrisksanduncertainties,andarenottobeconsideredguaranteesofanyparticularoutcome

Thisreportshallnotbepublished,norshallanypublicreferencestoIQVIAbemaderegardingtheseservicesorthisreport,withoutIQVIA’priorwrittenapproval.Whensoprovided,thisreportandtheinformationhereinmustalwaysbeprovidedandusedinitsentirety,includingthiscompleteDisclaimerpage

ThisreportissubjecttotheIQVIAGeneralTermsandConditions.

1

Marketreflectedgrowthof6%inQ12024

•OverallIPMmarketsize:₹216092Cr.(MATMar);₹53,337Cr(Q1Mar2024)

•GrowthinSalesValuePreviousPeriodGrowth(‘PPG’):8%(MAT);6%(Q12024)

•ChronicTAsgrewat10%PPGwhereasAcuteTAsreflectedsingledigitgrowthof3%PPGinQ12024

AmongstChronicTAs,Cardiacregisteredrobustgrowthof11%(PPG)andalsoledin

termsofabsoluteincrementalvalue,followedbyNeuro/CNS8%(PPG),AntiDiabetic7%(PPG)andChronicRespiratory6%(PPG)

Antineoplast,Pain,Uroalsoregistereddoubledigitgrowth

Anti-infectivesreflecteddegrowthof-2%(PPG).Gastrogrewat5%(PPG)andVMNgrewat7%(PPG)

RespiratoryAcutedegrewat-9%(PPG)

PainAcuteandDermagrewinsingledigits.

Relativeperformance:IndianPharmaCosgrewat6%(PPG)comparedtoMNCswhichgrewat5%(PPG)forQ12024

Sun,Cipla,Mankind,IntasreflectedgoodgrowthamongTopIndianPharmaCo’swhile

Abbott,Sanofi,Janssen,AstrazenecareflectedgoodgrowthsamongTopMNCPharmaCo’s

•Numberofnewlauncheshavedecreasedby-54%in2024ascomparedto2023

MATMar2024vs.MATMar2023aswellasQtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

MATProgress,Val₹‘000Cr.

+8%

201216

186

150

+10%

157

20202021202220232024

QTRProgress,Val₹’000Cr.

15%

10%

9%

8%

6%

10%

55

56

53

515052

Q4’22Q1’23Q2’23Q3’23Q4’23Q1’24

2

Pain

Gastro-Intestinal

Acute

Acutemarketgrowthof3%majorlyduetodeclineofAIandResp(Acute)marketandslowsingledigitgrowthfromPainandGItherapies

ChronicAcute

IPM40%60%53.3

Anti-Infectives

•Previousperiodgrowth:Value:-2%;Unit:-11%

Sequentialquartergrowth:Value:-11%;Unit:-15%

•Cephalosporins,whichcontributes~41%oftotalAItherapy,grewby-5%(PPG)growth.Macrolidesgrewby-10%(PPG)andQuinolones

werestagnantat0%(PPG)

•Azithromycincontributingto63%ofMacrolidesgrewat-11%(PPG)

•Ampicillin/Amoxycillingrewat-1%(PPG)

•Carbapenemsshowedgrowthof14%(PPG)majorlyduetoMeropenem15%(PPG)andFaropenem11%(PPG)

Respiratory(Acute)7%

47%

•Previousperiodgrowth:Value:-9%;Unit:-14%

Sequentialquartergrowth:Value:-10%;Unit:-12%

•Coughpreparationscontributing~53%oftotaltherapysaleshaveshowndegrowthof-17%PPG.LevosalbutamolandCombhave

-9%

8%

-2%

18%

10%

17%

5%

4%

showndegrowthof-6%PPGinCoughprepmarket

•ColdPreparationscontributingto15%grewat-6%(PPG)majorly

duetoColdPrepLiqmarketwhichgrewat-11%PPGand

AIPainGIOthersRespi

Antihistamines,systemiccontributingto17%reflectedgoodgrowth

of6%(PPG)

•Previousperiodgrowth:Value:4%;Unit:-6%

Sequentialquartergrowth:Value:-7%;Unit:-11%

•Antirheumatic,Nonsteroidalmarketwhichcontributesto44%ofPainmarketreflectedgrowthof7%(PPG)drivingthegrowthforPain

market

•Anti-Pyreticshaveshowndegrowthof-6%(PPG),Musclerelaxants(contribution12%)hasshowngrowthof9%(PPG).Antirheumatics(contribution10%)reflected3%(PPG)

•ParacetamolOralSolidsandParaLiquidsbothhaveshowndegrowthat-15%(PPG)each

•Previousperiodgrowth:Value:5%;Unit:-3%

Sequentialquartergrowth:Value:1%;Unit:5%

•AntipepticulcerantsandLaxativeshavereflectedgrowthof5%and13%(PPG)respectively

•Pantoprazole+DomperidoneandRabeprazole+Domperidonecontinuetogrowat7%and5%(PPG)respectively.

Qtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

3

Cardiac

Respiratory(Chronic)

Anti-Diabetes

Neuro/CNS

Chronic

Chronictherapiesdisplayedgrowthof10%(PPG)

ChronicAcute

53.3

IPM40%60%

•Previousperiodgrowth:Value:11%;Unit:2%Sequentialquartergrowth:Value:3%;Unit:0%

•Statins&Hypotensivesbothgrewat9%(PPG)and11%(PPG)respectively.Theytogethercontribute~38%ofTAsales

•OtherCardiactherapiesviz.HypotensiveDiuretics,ARBhaveregistereddoubledigitgrowth

•Anticoagulantsgrewby11%(PPG)majorlyduetoEnoxaparin,

TicagrelorandApixabangrowingat10%(PPG),17%(PPG)and41%(PPG)respectively

•Previousperiodgrowth:Value:6%andUnit:-4%

Sequentialquartergrowth:Value:-4%andUnit:-9%

•BronchodilatorsInhalationmarketshowedagrowthof12%(PPG)

•Montelukast+LevocetrizineSolidgrewat-4%(PPG)growth

•Bilastine+Montelukastshowedgrowthof13%(PPG)

14%

17%

11%

32%

23%

11%

6%

16%

20%

•Previousperiodgrowth:Value:7%;Unit:1%

Sequentialquartergrowth:Value:1%Unit:-2%

•Glimepiride+Metformin(TraditionalOralAnti-Diabetes)contributingto~23%todiabetestherapyhasshowngrowthof4%(PPG)

•Glimipiride+Metformin+Voglibosecontributingto~9%todiabetestherapyhasalsoreflected8%(PPG)

•Insulinmarketshowedsingledigitgrowthof2%(PPG)

•GLP1Agonistmarketreflectedgrowthof49%(PPG)

7%

•Previousperiodgrowth:Value:20%;Unit:11%Sequentialquartergrowth:Value:-3%Unit-3%

•Anti-EpilepticsandAnti-Depressant,whichtogetherconstitute51%oftheTA,grewat9%(PPG)and6%(PPG)respectively

•Gabapentin+NortriptylinwithinAntiepilepticshasshownhighgrowthof19%(PPG)andBrivaracetamshowedfastestrateofgrowthof37%(PPG)

OthersAnti-DiabetesNeuroRespiCardiac

Qtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

4

Geography

SouthandNorthzonescontinuetobehighestcontributingzones.MetrosandClass1marketgrewat7%each.ExtraUrbanmarketshowed3%growth

ZonalDynamics

Qtr.Jan-Mar23:₹53,337Cr.,QOQGr(6%)

(6%)North

27%

22%

27%

(5%)South

West(7%)

East(5%)

24%

•South&Northareleadingzonesbycontribution;Southgrowingat5%PPGandNorthat6%PPGwithmostincrementalsalescomingfromUttarPradesh,Delhi,TamilNadu,TelanganaandPunjab.

•Westzoneshowedgrowthof7%duetoMaharashtra,MadhyaPradesh,GujaratandGoaregions.However,Mumbaishowedslowgrowthof2%PPG

•Eastzone’sgrowthof5%wasdrivenbyChhattisgarh,Assam,Orissa,JharkhandandWestBengal.KolkataandBiharshowedslowrateofgrowthat3%and1%

respectively

•Amongstthetop15regions,UttarPradesh(4%PPG),Maharashtra(6%PPG),

TamilNadu(8%PPG),Telangana(7%PPG),Delhi(11%PPG),Gujarat(8%PPG)andMadhyaPradesh(10%PPG)werethetopgrowingregions.

TownClassAnalysis

Qtr.Jan-Mar23:₹53,337Cr.,QOQGr(6%)

(7%)

(3%)35%

34%

Metro

Class1

31%

(7%)ExtraUrban

•ExtraUrbanreflectedgrowthof3%PPG

•MetrosandClass1bothgrewat7%PPGeach

•MetrosindicatedhighergrowthsprimarilyledbyDelhi(11%PPG),

Hyderabad(8%PPG),Bangalore(6%PPG),Chennai(8%PPG),Pune(12%PPG),Lucknow(8%PPG)andAhmedabad(16%PPG)

•MetroslikeMumbai(2%PPG),Calcutta(3%PPG),Patna(-0.1%PPG),

Varanasi(2%PPG),Surat(1%PPG)grewataslowerratepullingdowntheoverallgrowthoftheMetromarket

MATMar2024vs.MATMar2023aswellasQtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

5

ChronicTherapies

CardiacTherapy

24,502+10%26,947

17,936

20,268

22,481

ValueinINRCr

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

Unitsin‘000

+2%

2,702,8552,831,6772,821,2282,809,5562,864,498

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

Q22023

(Apr-Jun’23)

Q32023

(Jul-Sept’23)

Q42023

(Oct-Dec’23)

Q12024

(Jan-Mar’24)

CardiacTherapy

*PPG(Value):10%

Statins,Hypotensivdualcomband

Anticoagulants,CCB,Diuretics

performedwell

Hypotensivediuretic,Betablocker,ARBsreflectedsingledigitgr

*PPG(Value):10%

GrowthwasdrivenmajorlybyAnticoagulantsat15%,

whilerestotherslikeStatins,

Hypotensivdualcomb,CCB,Diuretics

showedsingledigitgr

*PPG(Value):9%

Anticoagulantshavebeenthe

majordriverforgrowthfollowed

byDiuretics

Statins,Hypotensivcombs,

CCB,ARBsreflectedsingledigit

gr

*PPG(Value):11%

Hypotensivedualcomb,

Anticoagulants,Diuretics

showedbettergrowththanthe

market

Statins,HypoDiuretic,

Betablockersshowedslower

thanmarketgr

AnticoagulantshavebeenthemajordriverfortheFYApr’23-Mar’24periodowingtogrowthcomingfromApixaban,Ticagrelorand

Enoxaparin;AmongstStatins,RosuvastatinandcomboutperformedAtrovaandcombmarket.Telmisartanandcombwerepreferredover

otherARBcombs

Marketgrewatasteadyrateof2%(Unit-wise)atMATlevel.

Therewereatotalof244NIinFYApr’23-Mar’24periodoutofwhich235werelaunchedbyIndianCompanies

6

*PPGispreviousperiodgrowthi.e.Jan-Mar’24growthoverJan-Mar’23

MATMar2024vs.MATMar2023aswellasQtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

ChronicTherapies

MAT

7

DiabetesTherapy

14,42115,69716,88718,04919,128

ValueinINRCr

+6%

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

1,475,2801,553,2601,576,6351,593,6921,607,334

Unitsin‘000

+1%

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

Q22023

(Apr-Jun’23)

Q32023

(Jul-Sept’23)

Q42023

(Oct-Dec’23)

Q12024

(Jan-Mar’24)

DiabetesTherapy

*PPG(Value):7%

SGLT2+Dpp4performedwell

amongstNovelcombwhereasSu

plain+MetandTradTriplecombdid

wellamongstTradcomb

PlainSGLT2andplainDpp4

showednegativegrwhereasInsulin

showedsingledigitgr

*PPG(Value):5%

GrowthwasdrivenbySGLT2+Dpp4at

88%andGLP1Agonistmarketshowed

highgronsmallerbase(99%PPG)

PlainSGLT2andInsulinmarketwere

steady(0%PPGgr)andDpp4showed

negativegr

*PPG(Value):6%

SGLT2+Dpp4continuedtogrow

at72%PPG.

Suplain+Metsloweddownin

termsofgrat4%PPGand

insulinreflect-1%grPPGDpp4

continuedtodegrowat-2%

*PPG(Value):7%

SGLT2+Dpp4pulledupwith

marketgr.TradTriplecomb

grewat8%PPG

InsulinandGLP1bothgrewat2%and49%PPGresp

OralAntidiabeticsmarketreflectedgoodgrowthintheFYApr’23-Mar’24periodowingtogrowthcomingfromSitagliptinandcombmarket(Sita+Met,Sita+Dapa,Sita+Dapa+Met).GLP1AgonistandDulaglutidealsoshowedgoodgrowthonasmallerbase

Marketgrewatasteadyrateof1%(Unit-wise)atMATlevel.

Therewereatotalof275NIinFYApr’23-Mar’24periodwithmajorlaunchesseeninDapaandcombmarket(113nooflaunches)

Mar2024vs.MATMar2023aswellasQtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

*PPGispreviousperiodgrowthi.e.Jan-Mar’24growthoverJan-Mar’23

ChronicTherapies

MAT

8

Respi(Chronic)Therapy

6,879

5,1985,220

ValueinINRCr

+9%

7,7098,414

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

1,641,8541,652,837

1,334,573

1,477,930

1,093,967

Unitsin‘000

+1%

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

Q22023

(Apr-Jun’23)

Q32023

(Jul-Sept’23)

Q42023

(Oct-Dec’23)

Q12024

(Jan-Mar’24)

Respi

(Chronic)Therapy

*PPG(Value):15%

BronchodilatorsInhalationmarket

showed18%PPGpullingupthe

marketgr

MontecombwithLevo,Fexo,

Bilastine,Acebrophyllinewithin

NonsterRespAntiflammatory

marketshoweddoubledigitgr

*PPG(Value):7%

BronchodilatorsInhalationmarket

continuedtogrowat13%PPGfollowedby

NonsterRespAntiflammatorymarketand

Bronchodilatorsmarketat10%and15%

PPGresp.Bilastine+Montegrewat21%

PPG

Monte+Levo(bothsolidandliq)marketreflectednegativegr

*PPG(Value):11%

BronchodilatorsInhalation

havebeenthemajordriver

forgrowthfollowedby

BronchodilatorsSolids

marketat13%PPG.

NonsterRespAntiflammatorymarketgrewat-1%

*PPG(Value):6%

BronchodilatorsInhalation

marketgrewat12%PPG

NonsterRespAntiflammatory

marketcontinuedtogrewat-1%

duetoMonte+Levomarket

negativegr

Inhalationmarketcontributingto~53%oftheChronicRespimarkethasbeenthemajordriverforgrowthintheFYApr’23-Mar’24period;

Marketgrewatasteadyrateof1%(Unit-wise)atMATlevel.

Therewereatotalof77NIinFYApr’23-Mar’24periodwhereinallwerelaunchedbyIndianCompanies

Mar2024vs.MATMar2023aswellasQtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

*PPGispreviousperiodgrowthi.e.Jan-Mar’24growthoverJan-Mar’23

AcuteTherapies

Anti-InfectivesTherapy

23,233

24,328

18,360

21,855

16,221

ValueinINRCr

+5%

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

5%

-

2,247,914

Unitsin‘000

2,683,970

2,678,507

2,824,2152,811,897

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

Q22023

(Apr-Jun’23)

Q32023

(Jul-Sept’23)

Q42023

(Oct-Dec’23)

Q12024

(Jan-Mar’24)

Anti-

InfectivesTherapy

*PPG(Value):11%

Cephalosporins,Macrolidesand

Carbapenemsreflecteddouble

digitgrandperformedwell

AmpicillinandQuinolonesboth

showedsingledigitgrat7%and

2%PPG

*PPG(Value):2%

Carbapenemscontinuedtogrowat13%PPG

Ampicillin,MacrolidesandQuinolonesgrewat-2%,-8%and-3%PPG

*PPG(Value):10%

Cephalosporinsgrewat12%PPGandCarbapenemsat20%

HoweverAmpicillin,Macrolides

andQuinolonesshowesingle

digitgrowth

*PPG(Value):-2%

OnlyCarbapenemsshowed

14%growthamongsttop5

groupsinAI

Cephalosporins,Ampicillin,

Macrolidesallgrewpullingdown

overallgrowthofAImarket

CephalosporinsandCarbapenemscontributingto43%and9%havebeenthemajordriverfortheFYApr’23-Mar’24periodandreflected

growthof5%and17%PPGatMATlevel.AmpicillinandMacrolidescontributingto19%and9%respshowedsluggishgrowthof1%and-1%

PPGrespatMATLevel

Marketgrewat-5%(Unit-wise)atMATlevel.

Therewereatotalof155NIinFYApr’23-Mar’24periodoutofwhich153werelaunchedbyIndianCompanies.TheNIsweremajorlylaunchedinCephalosporins,CarbapenemsandAmpicillinmarket

9

*PPGispreviousperiodgrowthi.e.Jan-Mar’24growthoverJan-Mar’23

MATMar2024vs.MATMar2023aswellasQtr.Jan-Mar2024vs.Qtr.Jan-Mar2023growth

Source:IQVIATSAMar2024

AcuteTherapies

Pain(Acute)Therapy

ValueinINRCr

+7%

13,893

11,760

9,558

12,985

9,659

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

3%

-

Unitsin‘000

2,683,2592,514,5293,065,3292,950,7682,868,420

MATMarch2020

MATMarch2021

MATMarch2022

MATMarch2023

MATMarch2024

Q22023

(Apr-Jun’23)

Q32023

(Jul-Sept’23)

Q42023

(Oct-Dec’23)

Q12024

(Jan-Mar’24)

Pain

(Acute)Therapy

*PPG(Value):11%

AntirheumaticnonsteroNon

NarcoticsAntipyreticandMuscleRelaxanatsshoweddoubledigitgr

TopicalRheumaticsgrewat3%

*PPG(Value):6%

MuscleRelaxantscontinuedtogrowat

10%PPG.Antirhheumaticnonsteroand

TopicalAntirheumaticsgrewat6%and

4%PPGresp

NonNarcoticsAntipyreticgrewat-1%PPG

*PPG(Value):7%

AntirheumaticnonsteroNon

NarcoticsAntipyretic,Muscle

RelaxanatsandTopical

Antirheumaticsallshowedsingle

digitgrof9%,6%,8%and3%

resp

*PPG(Value):4%

Antirheumaticnonstero,Muscle

RelaxantsandTopical

Antirheumaticsshowedsingle

digitgrof7%,6%and3%resp

NonNarcoticsAntipyreticgrewat-6%PPG

AntirheumaticandMusclerelaxantscontributingto44%and11%resphavebeenthemajordriverforgrowthinPain(Acutemarket)inthe

FYApr’23-Mar’24periodgrowingat8%and9%respatPPGMATLevel;Non-Narcotics(contribution22%)andTopicalRheumatics

(contribution10%)eachgrewat3%

OverallPain(Acute)marketdegrewat-3%(Unit-wise)atMATlevel.

Therewereatotalof218NIinFYApr’23-Mar’24periodoutofwhich211w